Products for Research Use Only

Gemfibrozil-d6

CAT: 0804-HY-B0258S-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0258S-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Gemfibrozil-d6 is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.
CAS Number
1184986-45-5
Product Name Alternative
CI-719-d6
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Cytochrome P450; PPAR
Type
Isotope-Labeled Compounds
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Field of Research
Metabolic Disease; Cardiovascular Disease
Purity
98.00
Solubility
10 mM in DMSO
Smiles
OC(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])CCCOC1=C(C=CC(C)=C1)C)=O
Molecular Formula
C15H16D6O3
Molecular Weight
256.37
Precautions
H302, H315, H319, H335
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Pahan K, et al. Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. J Biol Chem. 2002 Nov 29;277 (48) :45984-91. Epub 2002 Sep 18.|[3]Almad A, et al. The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice. Exp Neurol. 2011 Dec;232 (2) :309-17.|[4]Wang JS, et al. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos. 2002 Dec;30 (12) :1352-6.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported